Disclosed herein are otic formulations and compositions comprising growth factors. These otic formulations and compositions allow for the delivery of the growth factor to the outer, middle, and/or inner ear for the treatment of otic diseases and disorders.

Four major polymeric architectures, namely: (a) linear, (b) branched, (c) hyperbranched/dendritic and (d) cross-linked polymers, when formed by reaction of multifunctional alcohols, such as sugar-based alpha-, beta- or gamma-cyclodextrins, with multi-carboxylic acids form unique polyester copolymers. These copolymers have been demonstrated to substantially enhance the water-solubility and bioavailability of water insoluble compounds for a wide variety of uses.

The present invention relates to controlled release formulations for treating hearing loss and a method for preparing the same, and more particularly, to controlled release formulations for treating hearing loss prepared by dispersing a steroidal anti-inflammatory agent encapsulated in low molecular weight hyaluronic acid in an aqueous solution of high molecular weight hyaluronic acid and a method for preparing the same.

Active agents that bind to VEGF or a VEGF receptor and reduce the severity of a condition associated with BLB disruption and/or angiogenesis, for example anti-VEGF antibodies or tyrosine kinase inhibitor small molecules, can be locally, regionally or systemically administered to an individual with an otic disease or condition, such as Méniére's Disease, Autoimmune Inner Ear Disease, sensorineural hearing loss and noise-induced hearing loss, to alleviate symptoms of the disease or condition, for example, due to edema and endolymphatic dysfunction. An effective amount of these compounds can be delivered by intratympanic or intracochlear administration. Other methods of administration include, but are not limited to, topical, parenteral, subcutaneous, intraperitoneal and intranasal. Formulations may be, for example, for immediate release, sustained release, or controlled release.

A device for generating nitric oxide is disclosed. The device is configured for applying to either a body cavity or a surface of a subject in need thereof. Also disclosed is a method for the treatment of diseases or conditions with the device.

The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

Provided is a pharmaceutical composition that can be administered into the ear without any complicated operation and has a function of allowing a drug to be retained and slowly released in the ear. A pharmaceutical composition for otic administration, comprising one, or two or more drugs and a polymer, wherein when the complex viscosity of the pharmaceutical composition is measured using a rheometer under the conditions of a shear strain of 5% and an angular frequency of 50 rad/sec., while increasing the temperature from 25° C. to 37° C. at a heating rate of 1° C./10 sec., the complex viscosity is less than 1,650 mPa.Math.s at 25° C., and is from 1,650 mPa.Math.s to 100,000 mPa.Math.s at 10 minutes after reaching 37° C.

Disclosed are topical mucoadhesive compositions comprising hyaluronic acid or a salt thereof, choline alfoscerate, an ascorbic acid ester at a concentration ranging between 0.050% w/w and 0.0004% w/w, and at least one pharmaceutically acceptable excipient or carrier.

A tympanic membrane prosthesis includes a tubular body having a lumen extending therethrough and open at each of a proximal and distal end. The tubular body forms a structurally self-supporting, body compatible, and body absorbable device. The device is formed of a composite structure that includes an inner portion having an inside surface and an outer portion having an outside surface. The inside surface forms at least a portion of the lumen extending through the tubular body. The inside surface is adapted to provide less resistance to fluid flow than the outside surface. The outside surface is adapted to produce an inflammatory reaction in adjacent tissue at a tympanic membrane. The device is adapted for insertion into an opening through the tympanic membrane for placement with the proximal end and the distal end disposed on opposite sides of the tympanic membrane.

This invention relates to novel synergy, where the antimicrobial effects of microbicidal lipids are augmented with minor amounts of ethanol, in particular to augment the microbicidal effects for preventing infection in the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface of a mammal by virus, pathogenic bacteria or fungi.